Conexeu Sciences Inc. CNXU
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 531.24% | 456.10% | 432.64% | 6,630.26% | |
| Depreciation & Amortization | -18.18% | 235.29% | 966.67% | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 482.21% | 417.22% | 414.64% | 742.56% | |
| Operating Income | -482.21% | -417.22% | -414.64% | -742.56% | |
| Income Before Tax | -494.93% | -403.01% | -492.49% | -1,620.35% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -494.93% | -403.01% | -492.49% | -1,620.35% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -494.93% | -403.01% | -492.49% | -1,620.35% | |
| EBIT | -482.21% | -417.22% | -414.64% | -742.56% | |
| EBITDA | -484.88% | -418.59% | -413.49% | -- | |
| EPS Basic | -210.97% | -132.37% | -161.77% | -645.65% | |
| Normalized Basic EPS | -210.76% | -132.56% | -127.66% | -255.25% | |
| EPS Diluted | -210.97% | -132.37% | -161.77% | -645.65% | |
| Normalized Diluted EPS | -210.76% | -132.56% | -127.66% | -255.25% | |
| Average Basic Shares Outstanding | 91.26% | 116.40% | 126.27% | 131.43% | |
| Average Diluted Shares Outstanding | 91.26% | 116.40% | 126.27% | 131.43% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |